Baudax Bio Long Term Debt

As of the most recent data (September 2023), BXRX shows a long-term debt of $2.5M. That compares with $2.2M in the prior-year period — up 16.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BXRX's long-term debt is now $2.5M (was $2.2M) — a 16.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Baudax Bio is outperforming or lagging.

Tracking BXRX's long-term debt over time shows whether Baudax Bio is scaling, shrinking, or reshaping that part of the business. The current reading is $2.5M That compares with $2.2M in the prior-year period — up 16.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Baudax Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $2.5M) with ownership activity and broader fundamentals.

Baudax Bio's long-term debt is $2.5M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.